Notes to Accounts of Vilin Bio Med Ltd.

Mar 31, 2025

r. Provisions, Contingent Liabilities and Contingent Assets: Provisions are recognised when the Company has a Present
Obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying Economic
Benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Contingent
Liability is disclosed in case of a present obligation arising from past events, when it is not probable that an outflow of resources
will be required to settle the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognised in
Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible asset that arises from past events
and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not
wholly within the control of the Entity. Contingent Assets are not recognised in Financial Statements and are disclosed in the
Notes when it is virtually certain that economic benefits will inflow to the Company.

s. Earnings Per Share (EPS): Basic EPS is computed using the Weighted Average Number of Equity Shares outstanding during the
period. Diluted EPS is computed using the Weighted Average Number of Equity and Dilutive Equity Equivalent Shares outstanding
during the period except where the results would be anti-dilutive.

Capital Management: The Company''s Policy is to maintain strong capital base to maintain Investor, Creditor and Market
confidence and to sustain future development of the business. The Management monitors the Return on Capital as well as the
level of Dividends to Equity Shareholders. The Company monitors Capital using a ratio of ''Net Debt'' to ''Equity''. For this purpose,
Net Debt is defined as Total Debt, comprising Loans and Borrowings less Cash and Cash Equivalents and Current Investments.
The Company''s Net Debt to Equity Ratio is as follows:

1. Earnings Per Share (EPS): Basic EPS and Diluted EPS amounts are calculated by dividing the Profit for the year attributable to
the Equity Holders of the Company by the Weighted Average Number of Equity Shares outstanding during the year.

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006" is based
on the information available with the Company regarding the status of registration of such vendors under the said Act, as per
the intimation received from them on requests made by the Company. There are no overdue Principal amounts / Interest Payable
amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers
during the year or for any earlier years and accordingly, there is no Interest Paid or Outstanding Interest in this regard in respect
of payment made during the year or on balance brought forward from previous years.

5. Capital Commitment and Contingent Liabilities

a) Capital Commitment: There are no Capital Commitments outstanding as at Reporting Date (As at March 31, 2025: Nil)

b) Contingent Liabilities and Commitments: There are no Contingent Liabilities

6. Other Statutory Information:

1. The Company has not been declared Wilful Defaulter by any Bank or Financial Institution or Government or any authority.

2. The Company has not granted Loans or Advances in the nature of loans to Promoters, Directors, KMPs and the Related
Parties.

3. The Company does not have any transactions with Companies which are struck off.

4. The Company has considered the business segment as the primary reporting segment on the basis that the risk and returns
of the Company is primarily determined by the nature of products and services. Consequently, the geographical segment

has been considered as a secondary segment.

5. The Business Segment has been identified on the basis of the nature of products and services, risks and returns,
Management Structure and Internal Performance Reporting Systems. The Business Segment comprises of Manufacturing
and Selling of Pharmaceutical Products. Geographical segment is considered based on sales within India and outside India.

6. Previous Year''s figures have been regrouped/reclassified wherever necessary to correspond with the Current Year''s
classification/disclosure.

In terms of our attached Report of Even Date FOR VILIN BIO MED LIMITED

FOR PPKG AND CO
Chartered Accountants
FRN:0009655S

Sd/- Sd/- Sd/- Sd/- Sd/-

Girdhari Lal Toshniwal Madhusudhan Prasanna Lakshmi Hari Prasad Dhruv V

(Partner) Yadamakanti Venna Avula Todi

M. No.: 205140 Reddy

UDIN: 25205140BMOPDJ4623

Date: May 17, 2025 (Managing (Whole-Time (Chief (Company

Place: Hyderabad Director) Director) Financial Secretary)

Officer)

---

Mar 31, 2024

(s) Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognized when the Company has a Present Obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Contingent Liability is disclosed in case of a present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation or where no reliable estimate is possible. Contingent Liabilities are not recognized in Financial Statements but are disclosed in the Notes to Accounts. Contingent Asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or nonoccurrence of one or more uncertain future events not wholly within the control of the Entity. Contingent Assets are not recognized in Financial Statements and are disclosed in the Notes when it is virtually certain that economic benefits will inflow to the Company.

(t) Earnings per share (EPS)

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.

28. Capital Management

The Company''s policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital as well as the level of dividends to ordinary shareholders.

The Company monitors capital using a ratio of ''net debt'' to ''equity''. For this purpose, net debt is defined as total debt, comprising loans and borrowings less cash and cash equivalents and current investments.

The Company''s net debt to equity ratio as at 31st March 2024 and 31st March 2023 was as follows

29. Earning Per Share (EPS):

Basic EPS and Diluted EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the company by the weighted average number of Equity shares outstanding during the year.

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006” is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company. There are no overdue principal amounts / interest payable amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the year or for any earlier years and accordingly there is no interest paid or outstanding interest in this regard in respect of payment made during the year or on balance brought forward from previous year.

33. Capital commitment and contingent liabilities

a) Capital commitment

There are no capital commitment outstanding as at reporting date (as at March 31, 2024: NIL)

b) Contingent Liabilities and Commitments There are no contingent liabilities

34. OTHER STATUTORY INFORMATION:

(i) The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.

(ii) The Company has not granted Loans or Advances in the nature of loans to promoters, directors, KMPs and the related parties.

(iii) The Company does not have any transactions with companies which are struck off.

35. The Company has considered the business segment as the primary reporting segment on the basis that the risk and returns of the Company is primarily determined by the nature of products and services. Consequently, the geographical segment has been considered as a secondary segment.

The business segment has been identified on the basis of the nature of products and services, the risks and returns, internal organization and management structure and the internal performance reporting systems. The business segment comprises of manufacturing and selling of pharmaceutical products. Geographical segment is considered based on sales within India and outside India.

36. Previous year''s figures have been regrouped/reclassified wherever necessary to correspond with the current year''s classification/disclosure.